Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
The Spectrum Pharmaceuticals growth party is over.
Sharpen your pencils, it's Last Call quiz time.
Edward Perks, Senior Vice President, Franklin Templeton Investments, explains why he is moving away from long-duration fixed income and into equities with a focus on dividend plays.
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
The promise of low-cost gene sequencing could lead to a new era of personalized medicine, yielding new approaches for treating cancers and other serious diseases. The New York Times reports.
India’s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation. The New York Times reports.
Merck said Tuesday first-quarter earnings would fall below Wall Street's estimates, however, it still expects to reach its earnings forecast for the full year.
Despite the lingering debt crisis and an incubating recession in many nations of the European Union, many global companies say they are maintaining or even increasing their investments in the euro zone and elsewhere on the Continent. The NYT reports.
After investing oracle Warren Buffett cited reasons to drop Johnson & Johnson, Les Funtleyder, portfolio manager of Miller Tabak Health Care advised Buffett not to sell.
Vivus CEO Leland Wilson saw “a very powerful signal” that anti-obesity drug Qnexa would be approved.
Should you ditch JNJ stock if you had to raise capital? Warren Buffett said he would. Discussing whether investors should keep JNJ in their portfolios, with Les Funtleyder, Miller Tabak healthcare strategist.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."
What investors should take away from Vivus, as shares soar on FDA nod.
A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.
Perrigo CEO Joseph Papa appeared on Wednesday's "Mad Money."
Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.